Latest News & Features
article
Roy Waldron was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the legal section, as LSIPR reports. 14 August 2018
Big Pharma
Following a CJEU decision in July, and with two more cases on the horizon, Joel Beevers and Michael Pears of Potter Clarkson report on whether an active ingredient (or combination of active ingredients) is ‘protected by a basic patent’, as required for a supplementary protection certificate. 14 August 2018
article
Elaine Waller was selected in the LSIPR 50 2018 publication for her influence on the life sciences industry. She featured in the legal section, as LSIPR reports. 13 August 2018
Americas
AbbVie has taken Sandoz to court over its biosimilar version of Humira (adalimumab), heightening the dispute between the pair. 13 August 2018
Americas
Members of the Pharmaceutical Research and Manufacturers of America last year obtained the highest-ever level of investment for the industry group, recording $71.4 billion of funding in research and development. 13 August 2018
Asia-Pacific
South Korea-based Samsung has revealed plans to commit W25 trillion to pursue new technology in areas including biopharmaceuticals and artificial intelligence. 10 August 2018
Americas
Novartis and Breckenridge settled their differences over a generic version of Novartis’s cancer drug Afinitor earlier this week. 10 August 2018
Americas
Lorie Ann Morgan was selected in the LSIPR 50 2018 publication for her influence on the life sciences industry. She featured in the legal section, as LSIPR reports. 10 August 2018
Americas
The US Food and Drug Administration yesterday approved the first generic drug to receive a competitive generic therapy designation. 9 August 2018
Big Pharma
A proposed change to supplementary protection certificate rules in the EU could lead to the development of less innovative medicines, according to the Irish Pharmaceutical Healthcare Association. 9 August 2018